Lameh Fananapazir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lameh Fananapazir has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Saidi A. Mohiddin
William Harvey Research Institute, Barts and The London Faculty of Medicine and Dentistry, Queen Mary University of London, UK (S.F., C.D., D.H., G.W., E.S., S.K., E.S., S.B., J.M.K., S.A.M., M.P.L., F.M.M.-B.).
2 shared publications David A. Begley
Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
1 shared publicationDavid Begley
Inherited Heart Diseases Section, Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
1 shared publicationDorothy Tripodi
Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
1 shared publicationJoanna Shih
Electrophysiology and Inherited Heart Diseases Section, Cardiology Branch, Building 10, Room 7B-15, 10 Center Drive, MSC 1650, Bethesda, MD 20892-1650, USA
1 shared publicationJudith B. Winkler
Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
1 shared publication
Latest Publications
- 21 August 2003
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 26 (9) , 1887-1896
Efficacy of Implantable Cardioverter Defibrillator Therapy for Primary and Secondary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
Risk stratification and effectiveness of implantable cardioverter‐defibrillator (ICD) therapy are unresolved issues in hypertrophic cardiomyopathy (HCM), a cardiac disease that is associated with arrhythmias and sudden death. We assessed ICD therapy in 132 patients with HCM: age at implantation was 34 ± 17 years , and 44 (33%) patients were aged ≤ 20 years . Indications were sustained ventricular tachycardia (VT) or cardiac arrest (secondary prevention) in 47 (36%) patients, and clinical features associated with increased risk for sudden death (primary prevention) in 85 (64%) patients. There were 6 deaths and 55 appropriate interventions in 27 (20%) patients during a mean follow‐up period of 4.8 ± 4.2 years : 5‐year survival and event‐free rates were 96%± 2% and 75%± 5% , respectively. ICD intervention‐free rates were significantly less for secondary than for primary prevention: 64%± 7% versus 84%± 6% at 5 years, P = 0.02 . Notably, 59 of 67 events (cardiac arrest and therapeutic ICD interventions), or 88%, occurred during sedentary or noncompetitive activity. Incidence of therapeutic shocks was related to age but not to other reported risk factors, including severity of cardiac hypertrophy, nonsustained VT during Holter monitoring, and abnormal blood pressure response to exercise. ICD related complications occurred in 38 (29%) patients, including 60 inappropriate ICD interventions in 30 (23%) patients. However, 8 (27%) of the patients with inappropriate shocks also had therapeutic interventions. ICD is effective for secondary prevention of sudden death in HCM. However, selection of patients for primary prevention of sudden death, and prevention of device related complications require further refinement. (PACE 2003; 26:1887–1896)
- 21 August 2003
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 26 (9) , 1887-1896
Efficacy of Implantable Cardioverter Defibrillator Therapy for Primary and Secondary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
Risk stratification and effectiveness of implantable cardioverter‐defibrillator (ICD) therapy are unresolved issues in hypertrophic cardiomyopathy (HCM), a cardiac disease that is associated with arrhythmias and sudden death. We assessed ICD therapy in 132 patients with HCM: age at implantation was 34 ± 17 years , and 44 (33%) patients were aged ≤ 20 years . Indications were sustained ventricular tachycardia (VT) or cardiac arrest (secondary prevention) in 47 (36%) patients, and clinical features associated with increased risk for sudden death (primary prevention) in 85 (64%) patients. There were 6 deaths and 55 appropriate interventions in 27 (20%) patients during a mean follow‐up period of 4.8 ± 4.2 years : 5‐year survival and event‐free rates were 96%± 2% and 75%± 5% , respectively. ICD intervention‐free rates were significantly less for secondary than for primary prevention: 64%± 7% versus 84%± 6% at 5 years, P = 0.02 . Notably, 59 of 67 events (cardiac arrest and therapeutic ICD interventions), or 88%, occurred during sedentary or noncompetitive activity. Incidence of therapeutic shocks was related to age but not to other reported risk factors, including severity of cardiac hypertrophy, nonsustained VT during Holter monitoring, and abnormal blood pressure response to exercise. ICD related complications occurred in 38 (29%) patients, including 60 inappropriate ICD interventions in 30 (23%) patients. However, 8 (27%) of the patients with inappropriate shocks also had therapeutic interventions. ICD is effective for secondary prevention of sudden death in HCM. However, selection of patients for primary prevention of sudden death, and prevention of device related complications require further refinement. (PACE 2003; 26:1887–1896)
- 1 November 2001
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 24 (11) , 1639-1644
Dual Chamber Pacemaker Therapy for Mid‐Cavity Obstructive Hypertrophic Cardiomyopathy
BEGLEY, D., et al.: Dual Chamber Pacemaker Therapy for Mid‐Cavity Obstructive Hypertrophic Cardiomyopathy. Intracavitary LV obstruction is an important determinant of clinical outcome in hypertrophic cardiomyopathy (HCM). In a minority of patients the obstruction is at the level of the papillary muscles. Mid‐cavity obstructive HCM may be associated with a distal LV aneurysm and a worse prognosis. It is often not amenable to standard cardiac surgery for LV outflow obstruction. The long‐term effects (mean follow‐up 4.8 ± 2.9 years) of dual chamber (DDD) pacemaker therapy in 14 patients with mid‐cavity obstructive HCM (mean age 34 ± 16 years, range 15–65 years) were studied. Patients were evaluated by cardiac catheterization at baseline and 6 months to 1 year after receiving DDD pacemakers off all drug therapy. Symptoms were improved in all patients and NYHA functional class reduced from 2.8 ± 0.1 to 1.9 ± 0.4 (P < 0.0005). Intracavitary LV pressure gradients was reduced significantly (43 ± 36 vs 84 ± 31 mmHg at baseline, P < 0.0005). There was a significant associated reduction in apical LV systolic pressure (152 ± 37 vs 188 ± 34 mmHg, P < 0.001). In addition, there was a trend towards increased exercise tolerance (445 ± 123 vs 396 ± 165). Cardiac output and LV filling pressures were unchanged. In conclusion, chronic DDD pacing results in significant symptomatic and hemodynamic improvement in this uncommon but important subset of patients with obstructive HCM in whom the role of cardiac surgery is less well defined compared with the more typical outflow tract location of LV obstruction.
- 1 November 2001
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 24 (11) , 1639-1644
Dual Chamber Pacemaker Therapy for Mid‐Cavity Obstructive Hypertrophic Cardiomyopathy
BEGLEY, D., et al.: Dual Chamber Pacemaker Therapy for Mid‐Cavity Obstructive Hypertrophic Cardiomyopathy. Intracavitary LV obstruction is an important determinant of clinical outcome in hypertrophic cardiomyopathy (HCM). In a minority of patients the obstruction is at the level of the papillary muscles. Mid‐cavity obstructive HCM may be associated with a distal LV aneurysm and a worse prognosis. It is often not amenable to standard cardiac surgery for LV outflow obstruction. The long‐term effects (mean follow‐up 4.8 ± 2.9 years) of dual chamber (DDD) pacemaker therapy in 14 patients with mid‐cavity obstructive HCM (mean age 34 ± 16 years, range 15–65 years) were studied. Patients were evaluated by cardiac catheterization at baseline and 6 months to 1 year after receiving DDD pacemakers off all drug therapy. Symptoms were improved in all patients and NYHA functional class reduced from 2.8 ± 0.1 to 1.9 ± 0.4 (P < 0.0005). Intracavitary LV pressure gradients was reduced significantly (43 ± 36 vs 84 ± 31 mmHg at baseline, P < 0.0005). There was a significant associated reduction in apical LV systolic pressure (152 ± 37 vs 188 ± 34 mmHg, P < 0.001). In addition, there was a trend towards increased exercise tolerance (445 ± 123 vs 396 ± 165). Cardiac output and LV filling pressures were unchanged. In conclusion, chronic DDD pacing results in significant symptomatic and hemodynamic improvement in this uncommon but important subset of patients with obstructive HCM in whom the role of cardiac surgery is less well defined compared with the more typical outflow tract location of LV obstruction.
- 12 May 1999
- Published by American Medical Association (AMA) in JAMA
- Vol. 281 (18) , 1746-1752
Advances in molecular genetics and management of hypertrophic cardiomyopathy.
- 12 May 1999
- Published by American Medical Association (AMA) in JAMA
- Vol. 281 (18) , 1746-1752
Advances in molecular genetics and management of hypertrophic cardiomyopathy.